Ultimate K2 by Pure TheraPro Rx — Ingredients, Evidence & Safety

🟢 100/100

This product looks safe

No ingredients exceed tolerable upper intake levels
100% of ingredients have research evidence

A Label Compliance Grade

Product Label

📄 Open Full PDF View on NIH DSLD →

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

5 Drop(s) Serving Size

90 Servings

Vitamin Product Type

100% Evidence Coverage

Supplement Facts — Evidence Check

Vitamin K2

680 mcg

📊 5.7× RDA — above typical dose 📚 273 studies (Tier A: 9, B: 175)

RDA 0.12mg This product: 0.68mg

Other Ingredients

Medium Chain Triglycerides

Label Claims — Verification

❓ Nutrient

❓ All Other

❓ Structure/Function

All Other (100% of products) Structure/Function (84% of products) Nutrient (73% of products)

Target Groups

Vegan Vegetarian Adult (18 - 50 Years) Gluten Free Dairy Free

Product Information

📋 Directions for Use

Directions: Shake gently before use. Take up to five (5) drops daily or as directed by a healthcare practitioner. For best results, place drop(s) directly on or under your tongue. Drops may also be placed into juice or water. Consume with meals containing healthy fats.

⚠️ Warnings & Precautions

Contains: Tree nut (coconut)

Warning: Individuals taking medication, children and pregnant or lactating women should consult their healthcare practitioner prior to use.

Do not use if tamper seal is damaged.

Keep out of reach of children.

🧪 Formulation Notes

Full spectrum Supports bone, brain & cardiovascular health

Vegan

Non-GMO Soy + gluten free

Why you need both MK-4 & MK-7 The two forms are distributed differently and activate different proteins in the body - both are equally essential for good health. MenaQ7 Vitamin K2 and MK-7 A patented form of natural MK-7 derived from chickpea fermentation

Concentrated formula

Formulated to exclude: Fillers, gluten, wheat, soy, corn, yeast, animal or dairy products, shellfish, fish, peanuts, egg, ingredients derived from genetically modified organisms (GMO's), artificial preservatives, sweeteners or colors.

Formulated, tested & packaged in the USA

Additional Information

90 day supply

0.5 fl oz (15 mL) drops

Please retain box for reference

Drops MK-4 MK-7 1 100 36 2 200 72 3 300 108 4 400 144 5 500 180 # of Drops = Units in mcg New Please recycle

Storage: Keep tightly closed. Refrigerate for optimal freshness. May be kept in a cool, dry place away from direct sunlight.

GMP Certified Good Manufacturing Practice

Product Details

UPC / SKU X003E06JFT

DSLD Entry Date 2024-01-24

Product Type Vitamin

Form Liquid

Brand Pure TheraPro Rx

DSLD ID 305968

Data Updated 2026-04-11

Research Evidence

332 Research Sources

59 Avg Quality Score

220 Meta Analysis

56 Systematic Review

30 Rct

16 Clinical Trial

3 Guideline

3 Regulatory Source

1 Narrative Review

1 Other

1 Openfda Safety

A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism

Meta Analysis The Cochrane database of systematic reviews 2014

PubMed DOI Cochrane

A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome

Meta Analysis The Cochrane database of systematic reviews 2017

PubMed DOI

A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Meta Analysis The Cochrane database of systematic reviews 2016

PubMed DOI

A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome

Meta Analysis The Cochrane database of systematic reviews 2020

PubMed DOI

A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair

Meta Analysis The Cochrane database of systematic reviews 2025

PubMed DOI

A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation

Meta Analysis The Cochrane database of systematic reviews 2018

PubMed DOI

A Antiplatelet agents and anticoagulants for hypertension

Systematic Review The Cochrane database of systematic reviews 2022

PubMed DOI

A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy

Meta Analysis The Cochrane database of systematic reviews 2012

PubMed DOI

A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation